×
About 10,783 results

ALLMedicine™ Eczema Center

Research & Reviews  2,705 results

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04669808

Jan 19th, 2022 - Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and te...

A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT05029895

Jan 19th, 2022 - Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited number of adolescent p...

How effective are interventions to reduce Staphylococcus aureus in eczema?
https://doi.org/10.1111/cea.14093
Clinical and Experimental Allergy : Journal of the Britis... Banerjee N

Jan 17th, 2022 - How effective are interventions to reduce Staphylococcus aureus in eczema?|2022|Banerjee N,|

Prevalence and characteristics of atopic dermatitis among young adult females and males...
https://doi.org/10.1111/jdv.17929
Journal of the European Academy of Dermatology and Venere... Johansson EK, Bergström A et. al.

Jan 16th, 2022 - There is limited knowledge regarding prevalence and characteristics of Atopic Dermatitis (AD) among young adults in the general population. To study AD among young adults in a Swedish population-based birth cohort, with a particular focus on preva...

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05190770

Jan 13th, 2022 - The purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for ...

see more →

Guidelines  4 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

BSACI guideline for the diagnosis and management of peanut and tree nut allergy.
https://doi.org/10.1111/cea.12957
Clinical and Experimental Allergy : Journal of the Britis... Stiefel G, Anagnostou K et. al.

Aug 25th, 2017 - Peanut nut and tree nut allergy are characterised by IgE mediated reactions to nut proteins. Nut allergy is a global disease. Limited epidemiological data suggest varying prevalence in different geographical areas. Primary nut allergy affects over...

Guideline for the management of wounds in patients with lower-extremity venous disease:...
https://doi.org/10.1097/WON.0b013e31827179e9
Journal of Wound, Ostomy, and Continence Nursing : Offici... Kelechi TJ, Johnson JJ et. al.

Nov 10th, 2012 - This article provides an executive summary of the lower extremity venous disease (LEVD) evidence-based guideline produced by the WOCN Wound Guidelines Task Force. The target audience for this guideline is health care professionals who specialize i...

see more →

Drugs  739 results see all →

Clinicaltrials.gov  142 results

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04669808

Jan 19th, 2022 - Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and te...

A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT05029895

Jan 19th, 2022 - Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited number of adolescent p...

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05190770

Jan 13th, 2022 - The purpose of this study is find out whether Oleogel-S10 is an effective treatment for radiation dermatitis when it is used in combination with a standard wound treatment cream called triamcinolone. Oleogel-S10 has shortened the healing time for ...

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
https://clinicaltrials.gov/ct2/show/NCT04086121

Jan 11th, 2022 - To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05081557

Jan 10th, 2022 - Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns an...

see more →

News  687 results

FDA Approves Two Oral JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis
https://www.medscape.com/viewarticle/966698

Jan 14th, 2022 - The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them the first oral JAK inhibitors available for this indication in ...

Itch-dominant atopic dermatitis often flies under the radar
https://www.mdedge.com/dermatology/article/250417/atopic-dermatitis/itch-dominant-atopic-dermatitis-often-flies-under-radar
Doug Brunk

Jan 5th, 2022 - In the clinical experience of Jonathan I. Silverberg, MD, PhD, MPH, atopic dermatitis (AD) patients with severe itch and mild to moderate lesions often fall through the cracks on the road to optimal treatment.

Itch-Dominant Atopic Dermatitis Often Flies Under the Radar
https://www.medscape.com/viewarticle/966080

Jan 5th, 2022 - In the clinical experience of Jonathan I. Silverberg, MD, PhD, MPH, atopic dermatitis (AD) patients with severe itch and mild to moderate lesions often fall through the cracks on the road to optimal treatment. Dr Jonathan Silverberg That's because...

Does Atopic Dermatitis Pose an Increased Risk of Acquiring COVID-19?
https://www.medscape.com/viewarticle/965646

Dec 27th, 2021 - According to the best available evidence, patients with atopic dermatitis (AD) do not appear to face an increased risk of acquiring COVID-19 or becoming hospitalized because of the virus. "This is an area that will continue to evolve, and further ...

Atopic dermatitis: Identifying patients likely to benefit from long-term 2 mg baricitinib
https://www.mdedge.com/dermatology/article/250222/atopic-dermatitis/atopic-dermatitis-identifying-patients-likely-benefit

Dec 25th, 2021 - Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) are most likely to benefit from long-term 2 mg baricitinib therapy if affected body surface area (BSA) at baseline was 10%-50% and early clinical improvement in itch/skin.

see more →

Patient Education  36 results see all →